HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings

Key Points

• HC Wainwright raised Zevra Therapeutics’ FY2027 EPS estimate to $0.55 from $0.46 and maintained a Buy rating with a $26 price target. The firm projects EPS of $0.61 in FY2028, $1.13 in FY2029, and $1.69 in FY2030.
• Zevra’s latest quarterly results exceeded expectations, with EPS of $0.25 versus the $0.11 consensus and revenue of $39.66 million versus estimates of $33.88 million.
• Analyst sentiment remains favorable, with nine Buy ratings and two Holds producing a Moderate Buy consensus and an average price target of $27.14, well above the stock’s recent $11.56 opening price.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright raised their FY2027 EPS estimates for shares of Zevra Therapeutics in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of $0.55 per share for the year, up from their previous estimate of $0.46. HC Wainwright currently has a "Buy" rating and a $26.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Zevra Therapeutics' FY2028 earnings at $0.61 EPS, FY2029 earnings at $1.13 EPS and FY2030 earnings at $1.69 EPS.

A number of other analysts also recently commented on ZVRA. Guggenheim reduced their price objective on Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating for the company in a research report on Friday. Citizens Jmp upped their target price on Zevra Therapeutics from $25.00 to $28.00 and gave the company a "market outperform" rating in a research note on Thursday. BTIG Research reduced their target price on Zevra Therapeutics from $27.00 to $24.00 and set a "buy" rating for the company in a research report on Monday, July 27th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Thursday. Finally, Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a report on Monday, July 27th. Nine research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $27.14.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $11.56 on Monday. The stock's 50-day moving average price is $12.32 and its 200 day moving average price is $10.59. The firm has a market capitalization of $686.43 million, a price-to-earnings ratio of 12.57 and a beta of 0.91. Zevra Therapeutics has a 12-month low of $7.16 and a 12-month high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. The business had revenue of $39.66 million during the quarter, compared to analysts' expectations of $33.88 million.

Institutional Trading of Zevra Therapeutics

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Zevra Therapeutics by 6.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company's stock worth $238,000 after buying an additional 1,812 shares during the last quarter. Strs Ohio bought a new position in shares of Zevra Therapeutics in the first quarter valued at approximately $125,000. Creative Planning acquired a new position in shares of Zevra Therapeutics in the 2nd quarter worth approximately $92,000. Rhumbline Advisers boosted its holdings in shares of Zevra Therapeutics by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 83,221 shares of the company's stock worth $733,000 after acquiring an additional 8,636 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Zevra Therapeutics during the 2nd quarter worth approximately $255,000. 35.03% of the stock is owned by institutional investors.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported quarterly EPS of $0.25 versus the $0.11 consensus estimate, while revenue reached $39.66 million, above expectations of $33.88 million. The company also posted a 42.82% net margin and positive operating cash flow. Zevra Therapeutics quarterly earnings report
• Positive Sentiment: Analysts remain bullish. Citizens raised its price target from $25 to $28 and assigned a “market outperform” rating. HC Wainwright maintained a “Buy” rating and a $26 target, while increasing its FY2026 EPS forecast to $0.57 from $0.55. Citizens price-target update
• Positive Sentiment: Regulatory and intellectual-property developments could improve MIPLYFFA’s long-term outlook. Zevra outlined a timeline for a CHMP reexamination opinion expected in the fourth quarter, while its MIPLYFFA Orange Book listing reportedly extends to 2041. Zevra CHMP and Orange Book update
• Neutral Sentiment: Guggenheim trimmed its price target to $23 from $24 but retained a “Buy” rating, leaving a target substantially above the current trading level. Guggenheim price-target update
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $0.13 from $0.17, signaling weaker near-term earnings expectations despite raising its full-year forecast.
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ZVRA investors. Although no allegations or findings were detailed, the announcement introduces legal and reputational overhang. Pomerantz investor investigation

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source